TOXICITY

CTCAE v6, v5 and v4: grade adverse events in seconds

The Common Terminology Criteria for Adverse Events (CTCAE) is the National Cancer Institute’s standard for describing and grading adverse events in cancer treatment and clinical trials.

ONCOassist brings CTCAE v6, v5 and v4 together in one searchable tool, helping oncology professionals quickly find adverse event terms and their grades at the bedside without scrolling through lengthy PDFs.

CTCAE adverse event grading in the ONCOassist app

What is CTCAE?

CTCAE is a descriptive terminology published by the US National Cancer Institute (NCI) for reporting adverse events (AEs). Each AE term comes with a severity scale, and the terms are grouped by MedDRA System Organ Class. CTCAE is used in most oncology clinical trials and widely in routine practice to grade toxicities consistently between clinicians, sites and studies.

The five CTCAE grades

Each adverse event term has its own grade definitions. The general principle across terms is:

Grade Meaning
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL or mild/moderate impact on age-appropriate normal daily activity.
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL or severe impact on age-appropriate normal daily activity.
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to the adverse event.

Not every term uses all five grades.

CTCAE v6.0: what changed from v5.0

NCI released CTCAE version 6.0 in 2025, following public consultation with the global oncology community. According to NCI, the main areas addressed are:

  • Grading adverse events in patients with abnormal laboratory values at baseline
  • Characterising adverse events associated with immunotherapies
  • Refining how cardiac adverse events are categorised

NCI also published a mapping resource that aligns every term and grade combination in v5.0 with v6.0, and each v6.0 term maps to a MedDRA Lowest Level Term. Some terms were restructured, for example several dermatology terms.

Examples of clinically relevant changes include ‘Bullous dermatitis’ replaced by ‘Dermatosis bullous’ and ‘Eczema’ by ‘Eczematous dermatitis’, together with the addition of more specific categories such as ‘Lichenoid dermatitis’ and ‘Dermatitis psoriasiform’. Outside dermatology, ‘Platelet count decreased’ becomes ‘Thrombocytopenia’, with changes to the thresholds separating grades 3 and 4. ‘Lymphocyte count decreased’ becomes ‘Lymphopenia’, recorded only as grade 1 (‘present’) in v6.0. These revisions warrant care when comparing adverse-event data across versions.

Which CTCAE version should I use?

For clinical trials, use the version specified in the protocol. NCI’s September 2025 implementation FAQ states that ongoing NCI CTEP/DCP studies using CTCAE v5.0 will continue with that version until study completion, with no requirement to convert previously collected data. For new NCI CTEP/DCP studies, v6.0 becomes mandatory when the Rave study build starts after Rave ALS 7.2 is released. Other studies may adopt v6.0 in accordance with their sponsor’s requirements.

Grading adverse events in ONCOassist

  • Search any CTCAE term and see every grade side by side
  • Switch between v6, v5 and v4 to match the trial protocol
  • Available offline on iOS and Android, and on the web app
  • Alongside the toxicity tools clinicians use with it: drug information, the drug interaction checker and the IO Toxicity tool

Grade adverse events in ONCOassist

Free for healthcare professionals on iOS, Android and the web.

Frequently asked questions

What does CTCAE stand for?

Common Terminology Criteria for Adverse Events. It was formerly known as the Common Toxicity Criteria (CTC or NCI-CTC).

Who publishes CTCAE?

The US National Cancer Institute (NCI), part of the National Institutes of Health.

When was CTCAE v5.0 published?

27 November 2017.

Is CTCAE v6.0 available in ONCOassist?

Yes. ONCOassist includes CTCAE v6, v5 and v4.

Is ONCOassist free?

Yes. ONCOassist is free for healthcare professionals.

Sources

Medically reviewed by Dr. Lakshmi Ramachandran, MBBS (JIPMER, India), CCEPC, MD Radiation Oncology (JIPMER, India), Clinical Officer, ONCOassist. Last reviewed November 2026.